Pioglitazone associated with relative risk reduction in recurrent stroke
The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative risk reduction in recurrent stroke.
Wilcox, Robert, Marie-Germaine Bousser, John Betteridge, Guntram Schernthaner, Valdis Pirags, Stuart Kupfer, and John Dormandy; for the PROactive Investigators. Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04). Stroke. 2007; 38(3): 865-73. http://stroke.ahajournals.org/cgi/content/short/38/3/865